UVA School of Medicine emeritus professor Dr. Frederick G. Hayden helped design the trial and presented the results Wednesday ...

An international clinical trial has identified a medication that can help prevent symptomatic COVID-19 in people exposed ...

Medicines like Paxlovid exist to treat COVID in high-risk people by preventing the virus from multiplying if taken at the ...

An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

To maintain vaccine efficacy, WHO regularly updates influenza vaccine strains based on global epidemiological, virological, ...

The UK Health Security Agency (UKHSA) has recently launched a genomic surveillance programme to monitor the HCV and its ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

NanoViricides, Inc. (the “Company”)(NYSE American:NNVC), a clinical-stage global leader developing revolutionary broad-spectrum antiviral drugs that the viruses cannot escape, declared today that its ...

Influenza A and B patients had similar death rates by 90 days (13.4% vs 8.7%, respectively) and proportions of radiologic ...